We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Goals for treating T2D+CKD (1)
- CKD management
- CKD management: SGLT2i
- Kidney outcomes in recent CVOTs with SGLT2i
- Kidney outcomes in recent HF trials with SGLT2i
- Canagliflozin vs placebo in T2D+CKD
- CREDENCE: secondary composite outcome sustained eGFR decline, ESKD, or renal death
- CREDENCE: SGLT2i reduces the secondary renal outcome of dialysis, transplantation or renal death
- CREDENCE: what slowing the eGFR decline could do
- DAPA-CKD: dapagliflozin vs placebo in CKD
- DAPA-CKD: benefits in patients with T2D+CKD
- DAPA-CKD: 50% decline in eGFR, ESRD, or CV death in participants with T2D+CKD
- DAPA-CKD: eGFR decline in patients with T2D+CKD
- Sustained GFR decline ≥ 50%, ESKD or renal death in T2D
- Acute kidney injury in T2D is reduced by SGLT2i
- CV mortality in T2D is reduced by SGLT2i
- CKD management: RAASi
- Global guidelines for T2D+CKD (2)
- RENAAL
- Meta-analysis: blockade of the RAAS reduces doubling of serum creatinine or kidney failure
- HHF in T2D+CKD is also reduced by ARBs
- Primary prevention of CKD in T2D with RAASi?
- Challenges with ACEi or ARB
- Renin-angiotensin system inhibition in advanced chronic kidney disease
- CKD management: statin
- Global guidelines for T2D+CKD (3)
- Intensive lipid lowering benefits patients with CKD
- Aggressive LDL lowering for CV risk reduction
- Statins and cardiovascular primary prevention in CKD
- The SHARP (Study of Heart and Renal Protection) trial (1)
- The SHARP (Study of Heart and Renal Protection) trial (2)
- Summary of statin trials
- CKD management: glucose
- Less progression, more regression with better glucose control
- Intensive glucose lowering fails to prevent “doubling of serum creatinine or ESKD” events
- No significant slowing of renal function decline
- Clinical trial follow-up
- CKD management: blood pressure
- Global guidelines for T2D+CKD (4)
- ACCORD-BP: subset of patients with T2D+CKD
- ACCORD-BP: patients with lower BP did not have slower kidney function decline
- ADVANCE-BP: patients with CKD have benefits
- CKD management: lipids
- ADDITIONAL lipid-lowering benefits patients with CKD
- ODYSSEY OUTCOMES: effect of alirocumab in patients with a recent acute coronary syndrome
- CKD management: weight
- Association of bariatric surgery with rates of kidney function decline
- Effect of an intensive weight-loss lifestyle intervention on kidney function
- Lifestyle interventions in patients with CKD not on dialysis
- CKD management: cardiovascular risk
- Global guidelines for T2D+CKD (5)
- Global guidelines for T2D+CKD (6)
- Primary prevention with aspirin in elderly patients with CKD
- 3P-MACE outcomes with GLP-1RA in patients with T2D + eGFR <60
- Kidney outcomes with GLP-1RA
- CKD management: ACR
- Global guidelines for T2D+CKD (7)
- FIDELIO-DKD: non-steroidal MRA slows eGFR decline
- FIDELIO-DKD: non-steroidal MRA improves renal and cardiovascular outcomes
- FIDELIO-DKD: non-steroidal MRA still has risks
- Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
- Goals for treating T2D+CKD
- TIMELY referral saves lives in patients with advanced CKD
- When to refer to a kidney specialty service?
- Comprehensive coordinated CKD care in 2023
- Conclusion
- Thank you for listening
Topics Covered
- Goals for treating T2D and CKD
- Multifactorial management
- SGLT2 inhibition
- RAAS blockade
- Statin therapy
- Risk-factor management
- Glucose control
- Antihypertensive treatment
- Further lipid lowering
- Weight control
- CV risk reduction
- Albuminuria
Links
Categories:
Therapeutic Areas:
External Links
Talk Citation
Thomas, M. (2023, August 31). Chronic kidney disease in type 2 diabetes: treatment [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/QSZI4852.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Merlin Thomas has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Chronic kidney disease in type 2 diabetes: treatment
Published on August 31, 2023
51 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. I'm Professor
Merlin Thomas from
the Department of Diabetes here
at Melbourne's Monash University
and it's my pleasure to
be talking to you about
"Chronic Kidney Disease
in Type 2 Diabetes."
In the previous
module I looked at
the pathogenesis of
diabetic kidney disease,
how it occurs and why glucose
drives it and some of
the mechanisms behind
it as well as the associations
with the complications
including obviously end-stage
kidney disease there's
also cardiovascular and
other complications.
In this particular module
we're going to focus on
how chronic kidney
disease in diabetes is
actually treated and the new
recommendations regarding
the management protocols for
chronic kidney
disease in diabetes.
0:49
Obviously when you
identify someone
with chronic kidney disease who
has diabetes there are a number
of priorities in terms
of your management.
The first most
obvious priority is
preserving what kidney
function is currently left.
Because when the GFR
declines in an individual
with diabetes,
it usually represents
an irreversible loss of
nephron mass filtering units
that maintain kidney function.
When those are lost,
it's irreversible,
they can't come back.
But what you can do
is protect what you
still have so that
further losses are
slowed and if possible
prevented by the therapy
that you initiate so that
the time it takes to develop
a severely impaired
kidney function
or essentially end-stage
kidney disease
requiring renal replacement
therapy is slowed and
if possible prevented entirely
in a patient's lifetime.
The second important goal
for treating patients
with type 2 diabetes and
chronic kidney diseases is
of course improving
their survival.
As you've heard in
the previous module
the presence and severity
of chronic kidney
disease in someone with
diabetes is a very
strong predictor of
poor outcomes including
impaired survival.
The treatment process
is essentially keeping
your patient alive
as much it is is to
preserving their
residual kidney function
and at the same time
if you're going to
keep your patients
alive the priority is to keep
them out of hospital and free of
complications that would reduce
their quality of life and
health status overall.
These three features are
intrinsically linked
there's really
no point in preserving
kidney function
if you're going to die
early or feel miserable.
Equally, if you can keep people
from feeling miserable and
preventing them to die early,
it's really important to
protect their kidney function
because you don't want them
then to end up on dialysis.
Enhancing their health and
also enhancing their
quality of life
is a critical
component of treating
type 2 diabetes and
chronic kidney disease.
Equally, when patients get to
advanced stages of
their chronic kidney
disease it's appropriate to
refer and plan for
management of end-stage
kidney disease whether that's
dialysis, kidney
transplantation or
a stage palliative
care without dialysis.
That is sometimes
appropriate for
our older and frailer patients.
But fundamentally the
most important goal and
usually the first thing
that we think are they
managing patients with
type 2 diabetes and
chronic kidney disease is
don't make things worse.
Because we understand
that patients with
type 2 diabetes and CKD
are at higher risk of
developing adverse
drug reactions and as
a result we are very risk
averse in the setting.
We tend not to initiate
new therapies in this
situation because we're always
worried that these are
the patients where adding
in something not only
doesn't give us much
gain but also gives us
much grief in terms of side
effects and complications.